Introduction {#S6}
============

Concurrent Chemoradiation (CRT) has been established as the standard treatment of locally advanced nasopharyngeal carcinoma (LANPC) based on the results of randomized clinical trials and a recent meta-analysis, which demonstrate a clear benefit of chemotherapy and radiotherapy in comparison to radiotherapy alone \[[@R1]-[@R7]\].

The Intergroup-0099 study demonstrated statistically significant overall survival (OS), disease free survival (DFS), and local-regional control (LRC) rate favoring CRT followed by adjuvant chemotherapy versus radiation therapy (RT) only. The study showed poor patient's compliance in the CRT group with only 55% undergoing adjuvant treatment and notably high local-regional failure and distant metastases rates \[[@R2]\]. Therefore, induction chemotherapy has been an attractive treatment approach.

Furthermore, identifying reliable prognostic markers would be of ultimate importance to individualize the management of patients with LANPC. However, the pre-treatment ^18^F-FDG positron emission tomography with computed tomography (PET-CT) has been investigated as a potential tool to predict treatment outcomes in patients with head and neck cancers, the diverse tumor sites, and inconsistent results limit those studies \[[@R8]-[@R15]\].

This is a retrospective study that aimed to assess the role of ^18^F-FDG-PET-CT maximum standardized uptake value (SUVmax) as a reliable predictive marker, and to report the treatment outcomes, and treatment induced adverse events in LANPC patients receiving induction chemotherapy in the form of Docetaxel, Cisplatin, and 5-Fu(TPF) followed by definitive CRT.

Patients and Methods {#S7}
====================

After obtaining the institutional review board, we reviewed charts of LANPC patients treated between January 2008 and December 2012. Eligible patients were diagnosed with LANPC stages; T1, N1-3, or T2-T4, any N according to American Joint Committee on Cancer Stage Classification System 6th Edition. All patients had baseline pretreatment PET-CT and received induction TPF chemotherapy followed by cisplatin based CRT. All patients signed informed consent. Other baseline imaging studies included computed tomography (CT), and/or Magnetic Resonance Imaging (MRI).

Chemotherapy {#S8}
------------

Patients received with 3 cycles of induction TPF chemotherapy; docetaxel 75 mg/m^2^ and cisplatin 75 mg/m^2^ on day 1, and continuous infusion of 5-fluorouracil 750 mg/m^2^/day days 1 to 5 every 21 days. During radiation treatment, cisplatin was administered concurrently either as 40 mg/m^2^ weekly or 100 mg/m^2^ every 3 weeks. Patients were evaluated by complete physical and laboratory investigations including complete blood count and serum chemistries before each cycle of induction chemotherapy. Complete tumor assessment including physical exam, and imaging studies (CT and/or MRI) was performed after induction chemotherapy and prior to CRT.

Radiation therapy {#S9}
-----------------

External beam radiation therapy (EBRT) was delivered by 3-dimensional conformal radiotherapy (3D-RT) or intensity modulated radiation therapy (IMRT) utilizing simultaneous integrated boost technique (SIB).

In patients treated with 3D-RT, each patient had three clinical-target-volumes (CTV). CTV1 included the pre-induction chemotherapy primary tumor volume and involved lymph nodes and was assigned to receive 70 Gy. CTV2 included nasopharynx, oropharynx, posterior two thirds of the anterior maxillary sinuses and non-involved upper neck nodes and received 60 Gy. CTV3 included lower non-involved neck nodes and received 54 Gy. Each CTV was expanded 5-10 mm to create the corresponding planning target volume (PTV). All patients received 1.8-2 Gy/fraction, 5 fractions/week. In patients treated with IMRT SIB, three PTVs were created (PTV1, 2, and 3) corresponding to CTVs 1, 2, and 3 in 2D-RT plans. Patient care before, during and after radiotherapy included maintaining good oral hygiene, dental care, adequate nutritional support and analgesia. Patients were assessed weekly during radiotherapy and toxicity was recorded and graded according to version 3.0 of the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) \[[@R16]\].

Pretreatment ^18^F-FDG-PET-CT scan {#S10}
----------------------------------

The PET scans were acquired with a PET/CT system (ECAT Exact HR+ SOMATOMA Project 10 CT Scanner /CTI PET systems (CPS), Siemens Medical Systems/Knoxville, TN). All patients fasted for at least 6 hours before PET scans and had serum glucose levels \<150 mg/dL. After intravenous injection of 370 MBq ^18^F-FDG, patients were kept in the resting state in a quiet, dimly lit room for 60 min. The CT component of the consisted of a 16-slice helical scanner with a gantry port of 70 cm. Images were acquired at \[[@R11]-[@R13]\] bed positions. The CT acquisition was performed before the emission acquisition. CT data were used for image fusion and for generation of the CT transmission map. The patients were positioned supine with their arms placed above the head for CT acquisitions. Per our protocol, low dose CT images were obtained with oral contrast only for attenuation correction. The PET component of ECAT HR+ isbismuth germi-nate-based.Emission data were acquired for \[[@R11]-[@R13]\] bed positions, at 2-3 min per bed position. The field of view was from the top of the head (vertex) to the proximal thighs. Total scanning time per patient was 22-39 min. The PET/CT images were retrospectively evaluated by a radiologist and nuclear medicine physician.

Follow up {#S11}
---------

Patients were assessed weekly during RT. Post treatment imaging studies included CT and/or MRI, and were scheduled 6-8 weeks after completion of the therapy. Tumor response was assessed according to response evaluation criteria in solid tumors (RECIST). Late radiation toxicity was assessed according to the RTOG/European Organisation for Research and Treatment of Cancer Late Radiation Morbidity Scoring Schema \[[@R17]\]. All patients were assessed at 3, 6, and 12 months during the first year, then every 6 months for 5 years, and then annually.

Statistical analysis {#S12}
--------------------

Disease free survival (DFS) and overall survival (OS) were calculated using the Kaplan Meier analysis. Log-rank test and Cox regression analysis were performed to correlate the various clinical and pathological parameters to treatment outcomes. All analyses were performed using SPSS 13.0 package program.

Results {#S13}
=======

This study included 70 LANPC patients who met the eligibility criteria and were treated consecutively between January 2008 and December 2012. The median age was 46 years (range 18-68) and the median follow up was 39.7 ± 10.9 months (range 14-58) for all patients. [Table 1](#T1){ref-type="table"} summarizes the baseline patients and disease characteristics.

Pretreatment ^18^F-FDG-PET-CT scan {#S14}
----------------------------------

All patients had pretreatment ^18^F-FDG-PET-CT. The PETCT SUVmax was calculated according to the following formula: SUV=tissue radioactivity concentration (MBq/g)/\[injected dose (MBq)/patient weight (kg)/decay factor of ^18^F\]. To minimize partial volume effects, the maximum-pixel SUV within a region of interest encompassing the tumor was used for further calculations. The median pretreatment primary tumor and lymph nodes SUVmax were 10.3 (range 3.2 to 24.3), and 8.5 (range 2.8 to 18.3) respectively.

Chemotherapy {#S15}
------------

Sixty-three patients (90%) received 3 cycles of induction chemotherapy, and seven patients received 2 cycles of induction chemotherapy due to Grade 3 nausea and vomiting in 4 patients and febrile neutropenia in three patients.

Twenty patients (28.5%) received standard tri-weekly concomitant cisplatin (100 mg/m^2^) treatment. Seven patients of them (35%) completed 3 cycles of tri-weekly cisplatin with 25% dose reduction in 3 patients due to grade 3 mucositis, dermatitis and neutropenia, while 10 patients (50%) tolerated 2 cycles and only three patients (15%) had 1 cycle. The other 50 patients (71.4%) received concomitant cisplatin (40 mg/m^2^) on weekly basis. Of these patients, three patients (6%) received 3 weeks of weekly cisplatin, six patients (12%) had 4 weeks, 18 patients (36%) had 5 weeks, and 23 patients (46%) had 6 weeks. Of the patients who received 6 weeks of concurrent weekly cisplatin, 20% dose reduction was applied on 5 patients due to development of grade 3 adverse events. After induction chemotherapy, nine patients (12.8%) achieved complete response, 54 patients (77.1%) had partial response, and 7 patients (10%) had stable disease.

Radiation therapy {#S16}
-----------------

Nineteen patients ( 27%) received IMRT utilizing SIB technique, while 51 patients (72.8%) were treated using 3D-RT. Total cumulative RT dose delivered ranged from 66 to 70 Gy (median 70 Gy).

Treatment outcomes {#S17}
------------------

All patients were assessed 6-8 weeks after definitive concurrent chemoradiation with radiologic imaging (CT and/or MRI). Sixty patients (85.7%) achieved CR and 10 patients (14.3%) had PR after treatment completion. On multiple linear regression analysis, the response achieved at the end of definitive CRT was significantly associated with tumor stage (P\<0.001), nodal stage (P=0.002), treatment breaks (P\<0.001) and the pretreatment PET-CT SUVmax (P=0.041). [Table 2](#T2){ref-type="table"} illustrates the association between different clinicopathological factors and response.

At a mean follow up time of 39.7 months, 13 patients (18.5%) relapsed. Three patients had local relapse only, five patients had distant metastases and five patients had both local and distant metastases. The 4-year OS and DFS rates were 86.7% and 78.6%, respectively ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The median DFS and OS intervals were not attained.

Receiver Operating Characteristic (ROC) curve was used to depict the ability of SUVmax to predict prognosis. Area under the curve was 0.564, and the best cut-off value was 8.0 ([Figure 3](#F3){ref-type="fig"}). On a univariate analysis, 4-years DFS was significantly higher in patients with pretreatment SUVmax \<8 (95%) vs. ≥ 8 (57.7%) (P=0.002) ([Figure 4](#F4){ref-type="fig"}). The 4-year DFS was also significantly associated with pretreatment T stage (P=0.01), N stage (P=0.02), treatment response (P\<0.001), and treatment breaks (P\<0.001). Additionally, patients with node SUVmax higher than that of the primary site had a significantly poorer DFS (55% vs 86.5%) respectively (P=0.01) ([Figure 5](#F5){ref-type="fig"}). Moreover, patients with an SUVmax \<8.0 had significantly better OS compared to those with an SUV of ≥ 8.0 (P=0.034). On a multivariate analysis, the SUVmax category was the only factor correlated with 4-year DFS (Hazard ratio=10.2, 95% C I 1.3-116.8, P=0.035). Moreover on defining the predictive value of SUVmax level in T stage categories (T1-2 and T3-4), the 4-year DFS was statistically significantly associated with SUVmax (\< 8 vs. ≥ 8) (P=0.003), but not overall survival (P=0.085) when stratified by T stage (T1-T2 vs. T3-T4).

Treatment induced adverse events {#S18}
--------------------------------

Induction chemotherapy was well tolerated, seven patients (10%) received only 2 induction cycles because of grade 3 toxicities, three (4%) of them developed grade 3 neutropenia and four (6%) patients had G3 nausea and vomiting. The most frequent acute toxicity encountered during chemoradiation was mucositis as 37 patients (53%) developed Grade 3 while only 4 patients (6%) suffered from Grade 4 mucositis, which necessitated hospitalization and discontinuation of treatment for 7-10 days.

Fourteen patients (20%) developed Grade 3 weight loss (10-19.9 Kg) while three patients (4.3%) had Grade 4 weight loss ≥ 20 kg during CRT ([Table 3](#T3){ref-type="table"}). Notably, the three patients who developed Grade 4 and eight of the patients who had Grade3 weight loss were initially those patients who refused the insertion of gastrostomy upfront prior the concurrent chemoradiation phase \[[@R18]\].

Discussion {#S19}
==========

The role of induction chemotherapy followed by concurrent chemoradiotherapy (CRT) is a matter of outstanding interest in LANPC because of the relatively high incidence of locoregional or distant metastasis of more than 40% due to the poor patient tolerance and limited penetration of adjuvant chemotherapy after CRT \[[@R19],[@R20]\]. Moreover, predicting the prognosis in those patients has become an important issue. Some reports demonstrated the value of pretreatment SUVmax as a predictive marker in patients with head and neck cancers \[[@R9]-[@R15]\]. However, we believe that further evidence is still required, especially among LANPC patients because the radiosensitivity, treatment strategy, and outcomes are quite different.

This study demonstrated that 3 cycles of TPF induction chemotherapy followed by CRT is a tolerable treatment modality with acceptable toxicity profile. The objective response rates (RR) were 89.6% (complete response (CR) was 12.5% and partial response (PR) was 77.1%) after induction TPF and 100% (CR in 85.7% and PR in 14.3%) after treatment completion. These results compare favorably with previous reports on induction chemotherapy. Bae et al. reported objective RR of 97% after induction chemotherapy (CR in 15.2% and PR in 81.8%) and 97% (CR in 69.7% and PR in 27%) after CRT (18). Similarly, Ekenel et al. reported objective RR of 87% and CR of 12% after induction and 100% objective RR with 95% CR after CRT \[[@R19]\].

In our study, the 4-year OS and PFS rates were 86.7% and 78.6%, respectively .The median DFS and OS intervals were not attained. Comparable survival rates have been reported. Bae et al. treated 32 LANC patients with TPF followed by CRT, PFS and OS rates were 75% and 86% respectively \[[@R18]\]. Hellenic Cooperative Oncology Group Study, evaluated induction cisplatin, epirubicin and paclitaxel chemotherapy to 47 patients, the 1-year OS was 93.5% and the 2-year PFS was 62% \[[@R20]\]. Ekenel et al. reported 94.9% and 84.7% 3 year OS and PFS, respectively \[[@R19]\]. Hiu et al. showed a clear OS benefit with this induction strategy, the 3-year PFS and OS were 88.2% and 94.1%, respectively \[[@R21]\].

Kong et al. reported the results of phase II trial on induction TPF followed by CRT using weekly cisplatin, the overall RR after RT was 90.2% and the 1-year OS was 100% \[[@R22]\].

The pretreatment ^18^F-^18^F ^18^F FDG-PET-CT-CT-CT, in addition to being used for the diagnostic work-up of patients with LANPC, ^18^F-FDG-PET-CT uptake, as measured by maximal SUV, showed a statistically significant association with DFS rate in NPC patients treated with CCRT \[[@R11]\]. In agreement with previous findings, our study demonstrated that LANPC patients treated by induction TPF chemotherapy followed by CRT with a base line SUVmax \<8.0 had a significantly superior DFS (95% vs 57%) (P=0.002) respectively compared to those with SUVmax ≥ 8. Similarly, lee et al. confirmed that NPC with an SUVmax \<8.0 had higher DFS than patients with SUVmax ≥ 8 (91% vs 51%) respectively, P=0.007 \[[@R11]\]. On a multivariate analysis, the SUVmax category was the only factor correlated with 4-year DFS (Hazard ratio=10.2, 95% C I 1.3-116.8, P=0. 035). Similarly, Liu et al. concluded on multivariate analysis that the SUVmax was the only significant variable for 5-year LFFS (p=0.017) and DFS (p=0.000) \[[@R14]\]. However, other studies demonstrated that the pretreatment FDG uptake is the only significant variable predicting survival and recurrence on multivariate analysis in LANPC patients, most of them were not specifically scrutinizing on patients receiving induction followed by CRT \[[@R8]-[@R15]\]. Our study also demonstrated that the 4-year DFS, and OS in T-stage (T1-2 versus T3-4) stratified by SUVmax level (\<8 vs. ≥ 8) were significantly associated with better DFS (P=0.003), but not for overall survival (P=0.085) favoring the SUVmax \<8. In contrast, Xie et al. demonstrated that the pretreatment SUVmax significantly affects the OS and DFS \[[@R15]\]. A possible explanation for our results not showing impact on OS when stratified by stage is that most of the patients with local-regional recurrence have survived after salvage treatment.

The most commonly encountered acute toxicities during induction chemotherapy were Grade 3 neutropenia, nausea and vomiting in 4% and 6% of patients respectively, which were uncomplicated and manageable. The most frequent acute toxicity encountered during CRT was mucositis as 37patients (53%). Moreover, fourteen patients (20%) developed Grade 3 weight loss (10-19.9 Kg) while three patients (4.3%) had Grade 4 weight loss ≥ 20 kg during the CRT phase. Similarly, Bae et al. reported that febrile neutropenia (9.1%), and nausea (9.1%) as the most notable grade 3 and 4 toxicities during induction chemotherapy phase, while mucositis (39.4%), fatigue (15.2%), and nausea (9.1%) were the most common grade 3 and 4 toxicities during CRT \[[@R18]\]. Additionally, Ekenel et al. reported that TC induction chemotherapy followed by CRT was well tolerated with a 10% rate of Grade 3/4 hematologic toxicity. There was no treatment related deaths \[[@R19]\]. Consequently, we believe that induction chemotherapy has an evolving role in the management of locally advanced NPC and is associated with tolerable toxicity profile. Pretreatment PET-CT SUVmax is a potential prognostic marker for LANPC patients receiving induction chemotherapy followed by CRT.

Conclusion {#S20}
==========

The pretreatment primary tumor PET-CT SUVmax is a potential independent prognostic predictor of clinical outcomes in patients with LANPC treated with TPF induction chemotherapy followed by CRT. A high ^18^F-FDG uptake (SUVmax ≥ 8) may indicate poor outcome in such patients.
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###### 

Patients and disease characteristics at baseline (N=70).

  Characteristic             No. of Patients   \%
  -------------------------- ----------------- -------
  **Age, years**                               
  Median                     46                
  Range                      18-68             
  **Sex**                                      
  Male                       52                75%
  Female                     18                25%
  **Pathological Subtype**                     
  Non keratinizing           13                18.5%
  Undifferentiated           50                71.4%
  Basaloid                   7                 10.1%
  **T stage**                                  
  T1                         7                 10.1%
  T2                         26                37.1%
  T3                         29                41.4%
  T4a,b                      8                 11.4%
  **N stage**                                  
  N0                         18                25.7%
  N1                         39                55.7%
  N2                         10                14.3%
  N3                         3                 4.3%
  **Stage group**                              
  II                         18                25.7%
  III                        43                61.4%
  IVA,B                      9                 12.9%

###### 

Association between response and other clinicopathological factors.

  ----------------------------------------------------------------------------
  Factor                            Patients no   P Value     
  --------------------------------- ------------- ----------- ----------------
  **Sex**                                                     **0.889**

  Male                              45 (64.2%)    7 (10.2%)   

  Female                            15 (21.4%)    3 (4.2%)    

  **Pathological subtype**                                    **0.133**

  Non keratinizing                  9 (12.9%)     4 (5.7%)    

  Undifferentiated                  45 (64.3%)    5 (7.1%)    

  Basaloid                          5 (7.1%)      2 (2.9 %)   

  **Baseline T stage**                                        ***\<0 .001***

  T1                                7 (10.1%)                 

  T2                                26 (37.1%)                

  T3                                25 (35.7%)    4 (5.7%)    

  T4                                3 (4.3%)      5 (7.1%)    

  **Baseline N stage**                                        ***0.002***

  N0                                18 (25.7%)                

  N1                                34 (48.6%)    5 (7.1%)    

  N2                                9 (12.9%)     1 (1.4%)    

  N3                                3 (4.3%)                  

  **Radiation Technique**                                     ***0.412***

  3DCRT                             48 (68.6%)    3 (4.2%)    

  IMRT                              15 (21.4%)    4 (5.8%)    

  **Concurrent Chemo-radiation**\                             ***\<0 .001***
  **Break**                                                   

  \<7 Days                          56 (80%)      4 (5.7%)    

  \>7 Days                          3 (4.3%)      7 (10 %)    

  **Pretreatment Pet- CTSUVmax**\                             ***041***
  **primary**                                                 

  \<8                               32 (45.7%)    6 (8.6%)    

  ≥ 8                               28 (40%)      4 (5.7%)    
  ----------------------------------------------------------------------------

###### 

Treatment related Grade 3&4 acute toxicities.

  ----------------------------------------------------------------------------------------
  Toxicity           Induction chemotherapy\   Chemoradiation\                  
                     No. of patients (%)       No. of patients (%)              
  ------------------ ------------------------- --------------------- ---------- ----------
  Mucositis          0                         0                     37 (53%)   4 (5.7%)

  Weight loss        0                         0                     14 (20%)   3 (4.3%)

  Esophagitis        0                         0                     10 (14%)   0

  Nausea/vomiting    4 (5.7%)                  0                     6 (8.5%)   0

  Anemia             0                         0                     1 (1.4%)   0

  Neutropenia        2 (2.8%)                  0                     4 (6%)     0

  Thrombocytopenia   0                         0                     3 (4.3%)   0

  Dermatitis         0                         0                     28 (40%)   0
  ----------------------------------------------------------------------------------------
